Hypersen Launches Its Coaxial 3D Line Confocal Sensor with the Industry-Minimum Lateral Resolution
16.11.2022 13:48:00 EET | Business Wire | Press release
As a leader in chromatic confocal technology, Hypersen is pleased to release a Coaxial 3D Line Confocal Sensor (HPS-LCX1000) for the global measurement & inspection market. This sensor offers an effective and high-precision (0.1µm) 3D inspection solution to the measurement and defects detection problems in the fields of semiconductors, consumer electronics, new energy, metal, automobile, and aviation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006199/en/
Hypersen releases a coaxial 3D line confocal sensor HPS-LCX1000 to tackle the difficulties in measurement and inspection of semiconductor wafer/chip, LED/OLED display, electronic components, metal, automotive and aerospace parts. It solves the shadowing problem when measuring targets with holes, steep slopes, and protruding components. (Photo: Business Wire)
Compared to current line confocal sensors, HPS-LCX1000 excels in its lateral resolution (1.1µm) and coaxial structure. Coaxial design means the incident and reflected rays overlap. Therefore, it solves the shadowing problem when measuring targets with holes, steep slopes, and protruding components.
In addition, it has the following advantages:
- High adaptability to various materials, especially transparent and highly reflective ones, mirrored surfaces, and even liquid
- Robust capability to measure complex geometric shapes
- Max. surface slope on mirror: ±45°
- Generate 2D image and 3D point cloud data by one scan
- Axial precision: 0.1µm
- Point density: 2,048 points/profile
- High scan speed: up to 35,000 lines/sec.
Separated sensor head and controller design greatly reduces the measurement error caused by heat generation of the sensor. Besides that, a 40G optical fiber enables low-latency data transmission between the sensor head and the controller. What’s more, the controller is equipped with an 8-core 64-bit CPU, high-speed FPGA and an AI accelerator. With integrated high efficient AI algorithm, HPS-LCX1000 reaches a scanning speed of 35,000 lines/sec. and enables real-time 3D point cloud data output.
What HPS-LCX1000 can do:
- 3D topography and dimension measurement
- Surface defects detection
- Curved surface measurement
- Displacement and roughness measurement
- Gap and flush measurement
- Thickness measurement of multi-layer transparent materials
Test engineers can find this sensor very helpful when conducting the following tasks:
- Wafer and PCB bumps 3D inspection
- Die defects detection
- IC chip pin 3D inspection
- Wire bonding defects detection
- Highly angled LED/OLED display profile measurement
- Smart watch components measurement
- Gluing effects inspection
- Automotive and aerospace components appearance inspection
About Hypersen Technologies:
Established in 2015, Hypersen manufactures and sells high-end optical and force torque sensors. As an innovative company in high-precision measurement field, Hypersen provides: 3D optical profilometer, 3D line confocal sensor, chromatic confocal sensor, high speed industrial camera, 3D LiDAR and 6-axis force torque sensor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006199/en/
Contact information
Media: Anney Kong anney_kong@hypersen.com
Technical support: Dylan Hou dylan_hou@hypersen.com
Orders: sales@hypersen.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom